MedTrace Logo

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.

Conditions

  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Interventions

DRUG

Etavopivat

400 mg once daily

Sponsors & Collaborators

  • Forma Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Transparency (dept. 2834), MD · Novo Nordisk A/S

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-07-15
Completion
2024-07-15
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05568225 on ClinicalTrials.gov